

Application No. To be assigned

Preliminary amendment dated October 23, 2003

In the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-96 (canceled).

97. (Newly Added) A crystalline form of nateglinide characterized by an XRPD pattern with peaks at 4.7, 7.4, 13.8 and 17.0+/-0.2 theta, wherein the crystalline form is substantially free of a peak at 3.8+/-0.2 theta.
98. (Newly Added) A crystalline form of nateglinide characterized by an XRPD pattern as substantially depicted in a figure selected from the group consisting of figure 65, figure 66, figure 67 and figure 68.
99. (Newly Added) A pharmaceutical formulation comprising the crystalline form of claim 97 or 98 and a pharmaceutically acceptable excipient.
100. (Newly Added) A method of lowering blood sugar level in a mammal comprising administering the pharmaceutical formulation of claim 99 to the mammal.

Amendment to the Drawings:

Please add figures 65 through 68.